And using tDCS for patients with depression with type I or II bipolar disorder, not only was the patient’s higher baseline IL-6 concentration associated with therapeutic efficacy, but the patient’s plasma IL-8 concentration also decreased significantly after treatment [21]. This evidence concerns the gene CXCL8 and depressive disorder.